2.55  -0.1 (-3.77%)		01-20 16:00
Open: 2.65 High: 2.7 Volume: 33,159		Pre. Close: 2.65 Low: 2.54 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	4.16	1-year :	4.96
Resists	First :	3.56	Second :	4.25
Pivot price	2.76
Supports	First :	2.44	Second :	2.03
MAs	MA(5) :	2.67	MA(20) :	2.92
	MA(100) :	4.41	MA(250) :	7.34
MACD	MACD :	-0.4	Signal :	-0.4
%K %D	K(14,3) :	17.2	D(3) :	21.2
RSI	RSI(14): 32.2
52-week	High :	21	Low :	2.44

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ACXP ] has closed above bottom band by 11.9%. Bollinger Bands are 72.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.7 - 2.72	2.72 - 2.74
Low:	2.5 - 2.52	2.52 - 2.54
Close:	2.52 - 2.56	2.56 - 2.58

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Fri, 16 Jan 2026
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Tue, 06 Jan 2026
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Wed, 12 Nov 2025
Acurx Pharmaceuticals Eyes Turnaround After Reverse Stock Split - Finimize

Wed, 12 Nov 2025
Acurx Pharma (NASDAQ: ACXP) ends quarter with $5.9M cash; R&D spend $0.4M - Stock Titan

Thu, 09 Oct 2025
Acurx Pharmaceuticals granted Australian patent for antibiotics - Investing.com

Wed, 08 Oct 2025
ACXP’s Steady Climb: New Developments? - timothysykes.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	2 (M)
Held by Insiders	6.1 (%)
Held by Institutions	7 (%)
Shares Short	81 (K)
Shares Short P.Month	13 (K)

EPS	-8.19
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.01
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-95.7 %
Return on Equity (ttm)	-291.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-0.32
PEG Ratio	0
Price to Book value	1.26
Price to Sales	0
Price to Cash Flow	-0.77

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.